ProCE Banner Activity

Expert Analysis: New Data Affecting European Clinicians From Fall 2019 HIV Conferences

Conference Coverage
Text Module

Chloe Orkin, MBChB, FRCP, MD, and Jürgen K. Rockstroh, MD, review new prevention, treatment, and outcome data from the 2019 IDWeek and EACS meetings that will affect practice for European clinicians managing HIV patient care.

Released: January 13, 2020

Expiration: January 11, 2021

No longer available for credit.

Share

Faculty

Chloe Orkin

Chloe Orkin, MBChB, FRCP, MD

Professor of Infection and Inequities
Faculty of Medicine and Dentistry
Queen Mary University of London
London, United Kingdom

Jürgen K. Rockstroh

Jürgen K. Rockstroh, MD

Head of Infectious Diseases
Professor of Medicine 
University Hospital Bonn
Bonn, Germany  

Provided by

Provided by the USF Health

ProCE Banner

Supporters

Supported by educational grants from

Gilead

ViiV Healthcare

Target Audience

This program is intended for physicians, pharmacists, and other healthcare providers who care for patients with HIV.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply data from studies of ARV agents used to prevent HIV infection
  • Devise management strategies based on the results of recent clinical studies of established ARV agents in HIV-infected patients
  • Appropriately counsel patients regarding the anticipated clinical role of new and investigational ART regimens

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty Disclosure

Primary Author

Chloe Orkin, MBChB, FRCP, MD

Professor of Infection and Inequities
Faculty of Medicine and Dentistry
Queen Mary University of London
London, United Kingdom

Chloe Orkin, MBChB, FRCP, MD, has disclosed that she has received funds for research support from and served on advisory boards and speaker bureaus for Gilead Sciences, GlaxoSmithKline, Janssen, Merck, and ViiV Healthcare.

Jürgen K. Rockstroh, MD

Head of Infectious Diseases
Professor of Medicine 
University Hospital Bonn
Bonn, Germany  

Jürgen K. Rockstroh, MD, has disclosed that he has served on advisory boards for Abivax, Gilead Sciences, Janssen, Merck, and ViiV Healthcare and has served on speaker bureaus for Gilead Sciences, Merck, and ViiV Healthcare.

Staff Disclosure

Staff

Jennifer M. Blanchette, Ph.D.

Clinical Editor
Clinical Care Options, LLC

Jennifer M. Blanchette, PhD, has no relevant conflicts of interest to report.

Joy Curzio, PhD

Editorial Contributor

Joy Curzio has disclosed that she has ownership interest in Advaxis, Editas, and OncoSec.

Edward King, M.A.

Vice President, Editorial
Clinical Care Options, LLC

Edward King, MA, has no relevant conflicts of interest to report.

Megan K. Murphy, PhD

Scientific Director

Megan K. Murphy, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Program Medium

This program has been made available online.

Participation in this self-study activity should be completed in approximately hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 13, 2020, through January 11, 2021:

1. Register online at httpProgram Medium

This program has been made available online.

 

Goal


The goal of this activity is to improve participants’ competence in integrating new agents into the treatment of patients with advanced RCC.

Goal


The goal of this activity is to improve learners’ competence in translating the most clinically significant data from 3 important scientific meetings into practical management strategies for persons at risk of or infected with HIV infection.